Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763502 | 0.81 | TDP1 (0.32) | TDP1MAPTSMN1; SMN2 | |
| SCHEMBL4772712 | 0.79 | ALDH1A1 (0.36) | TDP1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4762644 | 0.71 | DCTPP1 (0.49) | TDP1MAPTALDH1A1 | |
| SCHEMBL4767578 | 0.67 | DCTPP1 (0.38) | TDP1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4762679 | 0.65 | PDE5A (0.33) | TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4771049 | 0.64 | MAPT (0.37) | MAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL4770944 | 0.64 | ADORA2A (0.39) | TDP1MAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL480656 | 0.63 | KDM4E (0.53) | MAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL4762458 | 0.62 | PDE1A (0.44) | ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL10625381 | 0.62 | PKM (0.38) | TDP1MAPTALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | TDP1 4268/4885MAPT 4503/4885ALDH1A1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.